Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Evaluation of TRAIL receptors cell surface expression in MPM cell lines. Expression of TRAIL-R1, TRAIL-R2, TRAIL-R3 and TRAIL-R4 was evaluated by flow cytometry. The values represent the fluorescence intensity of the receptors normalized for the negative control. Data are expressed as mean ± s.d. from three independent experiments. *n.e.-not expressed

From: Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin

  TRAIL-receptors
MPM cell lines TRAIL-R1 TRAIL-R2 TRAIL-R3 TRAIL-R4
TRAIL-resistant     
H2052 14.0 ± 0.4 58.0 ± 3.1 2.6 ± 0.1 1.7 ± 0.4
SPC212 30.5 ± 0.2 64.0 ± 2.4 1.2 ± 0.1 4.2 ± 0.8
ZL34 10.9 ± 0.5 65.5 ± 4.2 1.5 ± 0.2 2.0 ± 0.5
H226 12.7 ± 0.8 66.6 ± 6.5 n.e* n.e
TRAIL-partially resistant     
SDM6 15.8 ± 0.3 33.6 ± 3.2 1.3 ± 0.1 n.e
SDM13 10.3 ± 0.2 15.3 ± 0.4 1.2 ± 0.3 1.4 ± 0.2
TRAIL-sensitive     
H2452 1.5 ± 0.1 34.0 ± 2.0 2.5 ± 0.2 1.7 ± 0.3
SCP111 33.0 ± 1.0 33.6 ± 1.5 2.1 ± 0.2 1.5 ± 0.2
ZL5 13.2 ± 0.2 55.7 ± 3.2 1.1 ± 0.1 1.3 ± 0.2
ZL55 32.8 ± 2.0 38.2 ± 3.5 n.e 1.2 ± 0.4
H28 26.4 ± 0.4 22.0 ± 0.8 1.3 ± 0.2 2.5 ± 0.5
SDM4 24.5 ± 0.3 58.0 ± 4.2 1.4 ± 0.2 1.5 ± 0.1
MSTO-211H 2.3 ± 0.1 60.4 ± 3.2 1.3 ± 0.3 1.3 ± 0.2